<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01061671</url>
  </required_header>
  <id_info>
    <org_study_id>689</org_study_id>
    <secondary_id>U10HL074424</secondary_id>
    <nct_id>NCT01061671</nct_id>
  </id_info>
  <brief_title>Simvastatin Therapy for Moderate and Severe COPD</brief_title>
  <acronym>STATCOPE</acronym>
  <official_title>Prospective Randomized Placebo-Controlled Trial of SimvaSTATin in the Prevention of COPD Exacerbations (STATCOPE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effect of daily administration of 40 mgms simvastatin taken for at least 12
      months (range 12-36 months) on the frequency of exacerbations of chronic obstructive lung
      disease (COPD) in patients with moderate to severe COPD who are prone to exacerbations and do
      not have other indications for statin treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COPD exacerbation is a common complication that significantly contributes to the high
      morbidity, mortality and costs associated with COPD. COPD exacerbations are associated with
      heightened lung inflammation that may have systemic implications (e.g., peripheral muscle
      weakness, cognitive impairment, depression, stroke, acute coronary syndrome, and
      atherosclerosis). Statins are potent agents that significantly reduce vascular events in
      patients with increased risks due to prior cardiac or cerebral vascular events and elevated
      lipid profiles. Statins have pleiotropic effects that extend well beyond their lipid lowering
      effects and may be potent anti-inflammatory agents. Retrospective data conducted in COPD
      patients indicate that statin use is associated with markedly decreased rates of COPD
      hospitalization and stabilization of lung function. Decreases in mortality in COPD due to
      complications of flu-like illnesses and deaths due to cardiovascular events have also been
      reported. Inflammatory biomarkers (C-reactive protein and interleukin- 6) are reported to be
      elevated in moderate to severe COPD patients who are prone to exacerbations. Inflammatory
      biomarkers (C-reactive protein and interleukin- 6) are reported to be reduced by statin
      therapy in patients with hyperlipidemia and cardiovascular diseases. Treatments that can
      effectively lessen the prevalence and severity of COPD exacerbations are desperately needed
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Futility
  </why_stopped>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of COPD Exacerbations</measure>
    <time_frame>up to 37 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to First COPD Exacerbation</measure>
    <time_frame>up to 37 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FEV1 (% Pred) From Baseline to Last Measure</measure>
    <time_frame>Baseline, last measure at up to 37 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Exacerbation COPD Hospitalization Rates (Events/Patient Year)</measure>
    <time_frame>up to 37 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">885</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>simvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 mgms of simvastatin daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo pill daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin</intervention_name>
    <description>40 mgms of simvastatin daily</description>
    <arm_group_label>simvastatin</arm_group_label>
    <other_name>Zocor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo pill daily</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects, 40-80 years of age.

          2. Clinical diagnosis of at least moderate COPD as defined by the GOLD criteria:

               1. Postbronchodilator FEV1(forced expiratory volume at one second)/FVC(forced vital
                  capacity) &lt; 70%,

               2. Postbronchodilator FEV1 (forced expiratory volume at one second) &lt; 80% predicted,
                  with or without chronic symptoms (i.e., cough, sputum production).

          3. Cigarette consumption of 10 pack-years or more. Patients may or may not be active
             smokers.

          4. Must meet one or more of the following 4 conditions

               1. Be using supplemental oxygenate

               2. Receiving a course of systemic corticosteroids and/or antibiotics for respiratory
                  problems in the past year,

               3. Visiting an Emergency Department for a COPD exacerbation within the past year, or

               4. Being hospitalized for a COPD (Chronic Obstructive Pulmonary Disease)
                  exacerbation within the past year

          5. Willingness to make return visits and availability by telephone for duration of study.

          6. Free of active coronary disease

          7. Subject with expected life expectancy &gt; 36 months

        Exclusion Criteria:

          1. Patients who:

               1. are on statin drugs.

               2. should be on statins based on established risk stratification using the ATP-III
                  (Adult Treatment Panel) to determine 10 year risk.

          2. Documented history of active coronary heart disease, such as unstable angina, prior
             myocardial infarction, stroke, symptomatic peripheral vascular or carotid artery
             disease, or congestive heart failure within the past 3 months.

          3. A diagnosis of asthma.

          4. The presence of a diagnosis other than COPD that results in the patient being either
             medically unstable, or having a predicted life expectancy &lt; 3 years.

          5. Special patient groups: prisoners, pregnant women, institutionalized patients

          6. Women who are at risk of becoming pregnant during the study (pre-menopausal) and who
             refuse to use acceptable birth control (hormone-based oral or barrier contraceptive)
             for the duration of the study.

          7. Woman using estradiol compounds for contraception. Postmenopausal women on estradiol
             compounds for hormone replacement therapy will be allowed into the trial.

          8. Participants otherwise meeting the inclusion criteria will not be enrolled until they
             are a minimum of four weeks from their most recent acute exacerbation.

          9. A clinical diagnosis of bronchiectasis defined as production of &gt; one-half cup of
             purulent sputum/day.

         10. Participants using niacin, azole antifungals (itraconazole, ketoconazole,
             posaconazole), fibric acid derivatives, erythromycin, clarithromycin, telithromycin,
             diltiazem, amlodipine , ranolazine,HIV protease inhibitors (such as indinavir),
             amiodarone, gemfibrozil, cyclosporine, verapamil, danazol, nefazodone, and red yeast
             rice extracts are excluded

         11. Active liver disease. Active liver disease is defined as ALT (alanine
             aminotransferase), AST (aspartate aminotransferase) as greater than 1.5 times the
             upper limit of normal.

         12. Patients with renal failure defined by serum creatinine greater than 3mg/dl.

         13. Alcoholism. Alcoholism is defined as &gt; 35 drinks per week. A drink is defined as one
             bottle of beer, one 8-ounce glass of wine, or one ounce of hard liquor.

         14. Hypersensitivity to HMG CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase
             inhibitors. Hypersensitivity is defined as an allergic reaction to statin, prior
             history of myopathy, rhabdomyolysis or previous intolerance to statin use.

         15. Participants drinking greater than 4 cups (1qt) of grapefruit juice per day.

         16. Participants drinking greater than 3 cups of green tea per day.

         17. Diabetics will be excluded. Diabetics are defined by:

        1. A CURRENT physician diagnosis of diabetes OR 2. CURRENT use of diabetic meds OR 3.
        Elevated HbA1c &gt; 6.5% 18. The discretion of the Principal Investigator that the potential
        participant will not be a reliable study subject to complete the study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John E Connett, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota (Data Coordinating Center)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven M Scharf, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Dransfield, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Washko, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital Boston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard K Albert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Denver Health Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Casaburi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harbor-UCLA Research &amp; Education Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dennis E Niewoehner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minnesota Veterans Affairs Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerard J Criner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Temple University Philadelphia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank Sciurba, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen C Lazarus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California at San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando J Martinez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Don Sin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Paul's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shawn Aaron, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ottawa Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veteran's Administration Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LA BioMed at Harbor-UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malcom Randall VA Medical Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois Health System</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LSU Health</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veteran's Administration Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reliant Medical Group</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veteran's Administration Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veteran's Administration Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HealthPartners Research Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55440</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovelace Respiratory Research Institute</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western New York Veterans Administration Healthcare System</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati VAMC</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital and Health Network</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Respiratory and Sleep</name>
      <address>
        <city>Langhorne</city>
        <state>Pennsylvania</state>
        <zip>19047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Lung Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pittsburgh VA Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Respiratory Specialists</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Sciences Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Columbian Hospital</name>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Surrey Memorial Hospital</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V1N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lion's Gate Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V7M2H9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Boniface Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Civic Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inspiration Research Limited</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 3A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie de Québec (Laval Hospital)</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2010</study_first_submitted>
  <study_first_submitted_qc>February 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2010</study_first_posted>
  <results_first_submitted>January 29, 2015</results_first_submitted>
  <results_first_submitted_qc>March 12, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 26, 2015</results_first_posted>
  <last_update_submitted>December 8, 2017</last_update_submitted>
  <last_update_submitted_qc>December 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>COPD</keyword>
  <keyword>Exacerbation</keyword>
  <keyword>Lung function</keyword>
  <keyword>Cardiovascular</keyword>
  <keyword>Smoking</keyword>
  <keyword>Statins</keyword>
  <keyword>Simvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Simvastatin</title>
          <description>40 mgms of simvastatin daily
Simvastatin: 40 mgms of simvastatin daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matched placebo pill daily
Placebo: Matched placebo pill daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="433"/>
                <participants group_id="P2" count="452"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="386"/>
                <participants group_id="P2" count="397"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Simvastatin</title>
          <description>40 mgms of simvastatin daily
Simvastatin: 40 mgms of simvastatin daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matched placebo pill daily
Placebo: Matched placebo pill daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="433"/>
            <count group_id="B2" value="452"/>
            <count group_id="B3" value="885"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.2" spread="8.5"/>
                    <measurement group_id="B2" value="62.3" spread="8.4"/>
                    <measurement group_id="B3" value="62.2" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="184"/>
                    <measurement group_id="B2" value="203"/>
                    <measurement group_id="B3" value="387"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="249"/>
                    <measurement group_id="B2" value="249"/>
                    <measurement group_id="B3" value="498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="429"/>
                    <measurement group_id="B2" value="445"/>
                    <measurement group_id="B3" value="874"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="190"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="328"/>
                    <measurement group_id="B2" value="346"/>
                    <measurement group_id="B3" value="674"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="362"/>
                    <measurement group_id="B2" value="376"/>
                    <measurement group_id="B3" value="738"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking History (Pack Years)</title>
          <units>Pack Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.0" spread="26.1"/>
                    <measurement group_id="B2" value="51.2" spread="28.7"/>
                    <measurement group_id="B3" value="50.6" spread="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Post‐bronchodilator FEV1 (forced expiratory volume at one second)</title>
          <units>liters (L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.19" spread="0.58"/>
                    <measurement group_id="B2" value="1.19" spread="0.56"/>
                    <measurement group_id="B3" value="1.19" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1/FVC (forced expiratory volume at one second/forced vital capacity)</title>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.44" spread="0.13"/>
                    <measurement group_id="B2" value="0.44" spread="0.13"/>
                    <measurement group_id="B3" value="0.44" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1 (% Predicted)</title>
          <units>percent predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.5" spread="17.8"/>
                    <measurement group_id="B2" value="41.6" spread="17.6"/>
                    <measurement group_id="B3" value="41.6" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Acute COPD Exacerbation requiring Hospitalization or ED visit within previous 12 mo</title>
          <description>Acute COPD (Chronic Obstructive Pulmonary Disease) Exacerbation requiring Hospitalization or Emergency Department visit within previous 12 months</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="216"/>
                    <measurement group_id="B2" value="238"/>
                    <measurement group_id="B3" value="454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="217"/>
                    <measurement group_id="B2" value="214"/>
                    <measurement group_id="B3" value="431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systemic glucocorticoid or antibiotic use within previous 12 mo</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="367"/>
                    <measurement group_id="B2" value="382"/>
                    <measurement group_id="B3" value="749"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Use of supplemental oxygen within previous 12 mo</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="222"/>
                    <measurement group_id="B3" value="420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="235"/>
                    <measurement group_id="B2" value="230"/>
                    <measurement group_id="B3" value="465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rates of COPD Exacerbations</title>
        <time_frame>up to 37 months</time_frame>
        <population>Analysis excludes participants without any follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>40 mgms of simvastatin daily
Simvastatin: 40 mgms of simvastatin daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo pill daily
Placebo: Matched placebo pill daily</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of COPD Exacerbations</title>
          <population>Analysis excludes participants without any follow-up data.</population>
          <units>exacerbations/person-year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="430"/>
                <count group_id="O2" value="447"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread="1.61"/>
                    <measurement group_id="O2" value="1.39" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.54</p_value>
            <method>negative binomial regression</method>
            <method_desc>Adjustments of confidence intervals for between-participant variation (overdispersion).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First COPD Exacerbation</title>
        <time_frame>up to 37 months</time_frame>
        <population>Analysis excludes participants without any follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>40 mgms of simvastatin daily
Simvastatin: 40 mgms of simvastatin daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo pill daily
Placebo: Matched placebo pill daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First COPD Exacerbation</title>
          <population>Analysis excludes participants without any follow-up data.</population>
          <units>Days to the first exacerbation</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="430"/>
                <count group_id="O2" value="447"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223" lower_limit="195" upper_limit="275"/>
                    <measurement group_id="O2" value="231" lower_limit="193" upper_limit="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in FEV1 (% Pred) From Baseline to Last Measure</title>
        <time_frame>Baseline, last measure at up to 37 months</time_frame>
        <population>Analysis excludes participants without any follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>40 mgms of simvastatin daily
Simvastatin: 40 mgms of simvastatin daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo pill daily
Placebo: Matched placebo pill daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FEV1 (% Pred) From Baseline to Last Measure</title>
          <population>Analysis excludes participants without any follow-up data.</population>
          <units>percent predicted</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="356"/>
                <count group_id="O2" value="356"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" lower_limit="-11.04" upper_limit="8.67"/>
                    <measurement group_id="O2" value="-1.81" lower_limit="-10.62" upper_limit="7.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.1461</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Exacerbation COPD Hospitalization Rates (Events/Patient Year)</title>
        <time_frame>up to 37 months</time_frame>
        <population>Analysis excludes participants without any follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>40 mgms of simvastatin daily
Simvastatin: 40 mgms of simvastatin daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo pill daily
Placebo: Matched placebo pill daily</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Exacerbation COPD Hospitalization Rates (Events/Patient Year)</title>
          <population>Analysis excludes participants without any follow-up data.</population>
          <units>events per patient year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="430"/>
                <count group_id="O2" value="447"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" lower_limit="0.24" upper_limit="0.38"/>
                    <measurement group_id="O2" value="0.31" lower_limit="0.23" upper_limit="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 37 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Simvastatin</title>
          <description>40 mgms of simvastatin daily
Simvastatin: 40 mgms of simvastatin daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matched placebo pill daily
Placebo: Matched placebo pill daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>ICD-9</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="178" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="190" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Cavernous Hemangioma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatic Heart Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Ischemic Heart Disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="433"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Pulmonary Circulation disorders</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="433"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="433"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Cardiac Dysrhythmias</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="433"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Heart Failure</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="433"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Orbital cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Esophagus and stomach disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Abdominal Hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="433"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="433"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Other Intestinal disorders</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="433"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Other Digestive Disorders</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="433"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Nissen Fundoplication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Ill defined digestive symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="433"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="433"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Severe Headaches</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Ill defined abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="433"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Sudden death of unknown cause</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="433"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Complications of surgical and medical care</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="433"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Respiratory Arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="433"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Abnormal Gait</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Other Infection</sub_title>
                <description>Pulmonary Aspergillosis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fractures</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="433"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Intracranial injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Internal Injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Trauma from motorcycle accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic disorders</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="433"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Dorsopathy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="433"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Rheumatism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="433"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Osteopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="433"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Degenerative Disc Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Liver Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Respiratory Cancer</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="433"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Bone Neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Genitourinary Neoplasm</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="433"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Lymphatic Neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Neuroendocrine Neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Central Nervous System disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental Disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="433"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Altered Mental Status</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrotic disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="433"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Other Urinary Disorder</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="433"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Disorders of the Male Genitourinary System</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Disorders of the Female Genitourinary System</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="40" subjects_affected="34" subjects_at_risk="433"/>
                <counts group_id="E2" events="32" subjects_affected="27" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="433"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="433"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Pneumoconioses</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>COPD Exacerbation</sub_title>
                <counts group_id="E1" events="155" subjects_affected="96" subjects_at_risk="433"/>
                <counts group_id="E2" events="187" subjects_affected="97" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>COPD other</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="433"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Other Respiratory</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="433"/>
                <counts group_id="E2" events="20" subjects_affected="13" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Ill Defined Respiratory events</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="433"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Hypoxemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="433"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Artery disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="433"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Vein disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="433"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>ICD-9</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="316" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="329" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="433"/>
                <counts group_id="E2" events="27" subjects_affected="23" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthropathies</sub_title>
                <counts group_id="E1" events="38" subjects_affected="25" subjects_at_risk="433"/>
                <counts group_id="E2" events="43" subjects_affected="32" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Dorsopathies</sub_title>
                <counts group_id="E1" events="35" subjects_affected="27" subjects_at_risk="433"/>
                <counts group_id="E2" events="32" subjects_affected="27" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Rheumatism</sub_title>
                <counts group_id="E1" events="89" subjects_affected="67" subjects_at_risk="433"/>
                <counts group_id="E2" events="73" subjects_affected="54" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Infection</sub_title>
                <counts group_id="E1" events="56" subjects_affected="26" subjects_at_risk="433"/>
                <counts group_id="E2" events="30" subjects_affected="23" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Infection</sub_title>
                <counts group_id="E1" events="159" subjects_affected="109" subjects_at_risk="433"/>
                <counts group_id="E2" events="166" subjects_affected="107" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="22" subjects_at_risk="433"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>COPD Exacerbation</sub_title>
                <counts group_id="E1" events="642" subjects_affected="232" subjects_at_risk="433"/>
                <counts group_id="E2" events="649" subjects_affected="244" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Other COPD Related Symptoms</sub_title>
                <counts group_id="E1" events="79" subjects_affected="41" subjects_at_risk="433"/>
                <counts group_id="E2" events="80" subjects_affected="43" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="94" subjects_affected="65" subjects_at_risk="433"/>
                <counts group_id="E2" events="90" subjects_affected="59" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination by the Data and Safety Monitoring Board due to futility in respect to a treatment effect. The original study population goal was 1200 and the study was terminated at 885 participants.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sarah Lindberg</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-626-9011</phone>
      <email>sharnden@ccbr.umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

